Inhibrx Biosciences (INBX) Common Equity (2023 - 2025)
Historic Common Equity for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $36.8 million.
- Inhibrx Biosciences' Common Equity fell 7936.31% to $36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 7936.31%. This contributed to the annual value of $133.6 million for FY2024, which is 20706.85% up from last year.
- Per Inhibrx Biosciences' latest filing, its Common Equity stood at $36.8 million for Q3 2025, which was down 7936.31% from $68.6 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Common Equity registered a high of $219.4 million during Q2 2024, and its lowest value of $36.8 million during Q3 2025.
- Moreover, its 3-year median value for Common Equity was $94.4 million (2025), whereas its average is $110.7 million.
- In the last 5 years, Inhibrx Biosciences' Common Equity soared by 20706.85% in 2024 and then tumbled by 7936.31% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Common Equity stood at $43.5 million in 2023, then soared by 207.07% to $133.6 million in 2024, then plummeted by 72.43% to $36.8 million in 2025.
- Its last three reported values are $36.8 million in Q3 2025, $68.6 million for Q2 2025, and $94.4 million during Q1 2025.